Add to ORKGThe impact on patients suffering from chronic hand eczema (CHE) is enormous, as no licensed systemic treatment option with proven efficacy for CHE is available. Alitretinoin is a novel agent which showed high clinical efficacy in patients with severe, refractory CHE. We assessed the cost-effectiveness of alitretinoin for CHE patient treatment from a Swiss third party payer perspective. A further objective of this study was to determine the burden of disease in Switzerland
Acitretin has been used off-label for years to treat chronic hand eczema, but acitretin is less ofte...
Alitretinoin is the only systemic agent approved to treat moderate-severe chronic hand eczema (CHE) ...
Background Little is known about the socio-economic burden of severe chronic hand eczema in patients...
International audienceTo assess AL effectiveness and safety in patients with sCHE under real-life co...
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiven...
Background Patients with severe chronic hand eczema (CHE) refractory to topical corticosteroids curr...
Background Patients with severe chronic hand eczema (CHE) refractory to topical corticosteroids curr...
Introduction: Chronic hand eczema (CHE) is a frequent skin disorder affecting up to 10% of the popul...
Background: Chronic hand eczema (CHE) tends to be refractory to conventional therapy. Previous clini...
Alitretinoin (9-cis-retinoic acid) is the only drug licensed for the treatment of severe chronic han...
Acitretin has been used off-label for years to treat chronic hand eczema, but acitretin is less ofte...
Alitretinoin is the only systemic agent approved to treat moderate-severe chronic hand eczema (CHE) ...
Background Little is known about the socio-economic burden of severe chronic hand eczema in patients...
International audienceTo assess AL effectiveness and safety in patients with sCHE under real-life co...
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiven...
Background Patients with severe chronic hand eczema (CHE) refractory to topical corticosteroids curr...
Background Patients with severe chronic hand eczema (CHE) refractory to topical corticosteroids curr...
Introduction: Chronic hand eczema (CHE) is a frequent skin disorder affecting up to 10% of the popul...
Background: Chronic hand eczema (CHE) tends to be refractory to conventional therapy. Previous clini...
Alitretinoin (9-cis-retinoic acid) is the only drug licensed for the treatment of severe chronic han...
Acitretin has been used off-label for years to treat chronic hand eczema, but acitretin is less ofte...
Alitretinoin is the only systemic agent approved to treat moderate-severe chronic hand eczema (CHE) ...
Background Little is known about the socio-economic burden of severe chronic hand eczema in patients...